MVM, a UK-based venture capital company, is set to launch its second biotechnology fund which will have a more international focus than the first.
MVM believes it will raise at least £100m (€157.3m). Stephen Reeders, chief executive at MVM, said: "We have already received pledges of £28m from our existing investors and will launch once we have reached £40m."
